Alvocidib Biomarker-driven Phase 2 AML Study
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Stephen Anthony, DO
Sumitomo Pharma America, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Princess Margaret Cancer Center
Toronto, Ontario, Canada
- Hospital Regional Universitario de Malaga
Málaga, Malaga, Spain
- Complejo Hospitalario Universitario de Albacete
Albacete, Spain
- Institut Catala D'Oncologia
Badalona, Spain
- Hospital Clinic de Barcelona
Barcelona, Spain
- Hospital San Pedro de Alcantara
Cáceres, Spain
- Hospital Universitario Central de Asturias - Huca
Oviedo, Spain
- Hospital Clinico Universitario de Salamanca
Salamanca, Spain
- Hospital Universitari I Politècnic la Fe
Valencia, Spain
- University Hospitals of Wales
Cardiff, Wales, United Kingdom
- Univ Hospital of Bristol
Bristol, United Kingdom
- Guys Hospital St. Thomas
London, United Kingdom
- Honor Health Research Institute
Scottsdale, Arizona, United States
- University of California Los Angeles (ucla)
Los Angeles, California, United States
- University of California San Diego Ucsd
San Diego, California, United States
- Mayo Clinic Florida
Jacksonville, Florida, United States
- Northside Hospital
Atlanta, Georgia, United States
- Northwestern Memorial Hospital
Chicago, Illinois, United States
- University of Iowa
Iowa City, Iowa, United States
- University of Kansas Medical Center
Westwood, Kansas, United States
- Ochsner Clinic Foundation
New Orleans, Louisiana, United States
- Sidney Kimmel Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Mayo Clinic Rochester
Rochester, Minnesota, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Morristown Cancer Center
Morristown, New Jersey, United States
- Roswell Park Cancer Center Institute
Buffalo, New York, United States
- Hudson Valley Cancer Center
Hawthorne, New York, United States
- Columbia University Medical Center
New York, New York, United States
- University of North Carolina
Chapel Hill, North Carolina, United States
- Duke
Durham, North Carolina, United States
- East Carolina University
Greenville, North Carolina, United States
- Cleveland Clinic Foundation
Cleveland, Ohio, United States
- Ohio State University
Columbus, Ohio, United States
- West Penn Allegheny Hospital
Pittsburgh, Pennsylvania, United States
- Baylor Sammons Cancer Center
Dallas, Texas, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Mar 2016
- Primary completion
- 12 Feb 2020
- Completion
- 12 Feb 2020
- Last update posted
- 15 Nov 2023
- Registered enrollment
- 104
- Registry id
- NCT02520011
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.